PRESS RELEASE. Sciety och Sciety Venture Partners have invested SEK 54 million in Neogap Therapeutics (Neogap), a Swedish clinical-stage biotech company that develops personalised immunotherapy for cancer treatment with the help of two emerging technologies. The company has also been awarded roughly SEK 29 million in innovation funding from the
PRESS RELEASE. Sciety’s portfolio company PharmNovo, a Swedish pharmaceutical company based in Lund, reports positive results in its clinical phase I study of a drug candidate for nerve pain – an area currently lacking safe and effective treatments. The company announces that the headline results of the study show that
INSIGHT. In recent years, we have seen a clear trend of smaller life science companies hiring contract research organizations, or CROs, to manage their preclinical and clinical studies. This trend is driven, among other things, by increased access to capital for early pharmaceutical companies in recent years. Some of
NEWS. In response to the increasing demand for Sciety’s services, we are happy to announce the addition of three new Communication Specialists to our team. At Sciety, we believe in the importance of clear investor communication. Communication is a fundamental part of what we do, ensuring that we cultivate trust
NEWS. Spring 2023 was an interesting time for Sciety. Our goal is to make scientific breakthroughs in medicine and technology available to people all over the world. This is why we strive to help innovative companies within life science and digital health to grow and reach their full potential. In
INSIGHT. Sweden has a long tradition of research and development in life science, supported by a well-functioning ecosystem that encourages collaboration and innovation and drives development forwards. This also lays the foundation for many of the companies that are started here, providing a great deal flow of investment opportunities